Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy

Diseases of the Esophagus

Volumn 18, Issue 6, 2005, Pages 370-373

  Rackoff, Andrew ^a   Agrawal, A ^a   Hila, A ^a   Mainie, I ^a   Tutuian, R ^a   Castell, D O ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

GERD; Histamine 2 receptor antagonist; Proton pump inhibitor; Tolerance

Indexed keywords

ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; PROTON PUMP;

ADULT; CHRONOTHERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERANCE; ESOPHAGITIS; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INTERVIEW; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NIGHT; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; SLEEP DISORDER; STOMACH FUNDOPLICATION; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; ARTICLE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION;

DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INTERVIEWS; MALE; PROTON PUMPS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33644831521     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2005.00518.x     Document Type: Review

References (30)

1. Peghini P L, Katz P O, Castell D O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
2. Xue S, Katz P O, Banerjee P, Tutuian R, Castell D O. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
3. Hatlebakk J G, Katz P O, Kuo B, Castell D O. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40.
4. Tutuian R, Katz P O, Ahmed F, Korn S, Castell D O. Over-the-counter H2-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors. Aliment Pharmacol Ther 2002; 16: 473-7.
5. Khoury R M, Katz P O, Hammod R, Castell D O. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13: 675-8.
6. Fackler W K, Ours T M, Vaezi M F, Richter J E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
7. Lachman L, Howden C W. Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57-61.
8. Mathot R A, Geus W P. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance. Clin Pharmacol Ther 1999; 66: 140-51.
9. Hatlebakk J G, Berstad A. Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scand J Gastroenterol 1996; 31: 954-8.
10. Merki H S, Halter F, Wilder-Smith C H. Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine. Gastroenterology 1993; 105: 748-54.
11. Wilder-Smith C H, Ernst T, Gennoni M, Zeyen B, Halter F, Merki H S. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990; 35: 976-83.
12. Castell D O. Nocturnal acid breakthrough in perspective: Let's not throw out the baby with the bath water. Am J Gastroenterol 2003; 98: 517-18.
13. Savarino V, Mela G S, Zentilin P et al. Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine. Fundam Clin Pharmacol 1996; 10: 304-8.
14. Castell D O et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
15. Hatlebakk J G, Katz P O, Kuo B, Castell D O. Medical therapy: Management of the refractory patient. Gastroenterol Clin North Am 1999; 28: 847-60.
16. Achem S R, Kolts B E, MacMath T et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42: 2138-45.
17. Katz P O, Castell D O. Medical therapy of supraesophageal reflux disease. Am J Med 2000; 108: 170S-77S.
18. Harding S M, Richter J E, Bradley L A et al. Asthma and gastroesophageal reflux: Acid suppression therapy improves asthma outcome. Am J Med 1996; 100: 395-405.
19. Orr W C, Harnish M J. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17: 1553-8.
20. Katz P O, Anderson C, Khoury R, Castell D O. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
21. Fouad Y M, Katz P O, Castell D O. Esophageal motility defects associated with nocturnal gastro-esophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1998; 13: 1467-71.
22. Ours T M, Fackler W K, Richter J E, Vaezi M F. Nocturnal Acid Breakthrough: Clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 545-50.
23. Qvigstad G, Arnestad J S, Brenna E, Waldum H L. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Scand J Gastroenterol 1998; 33: 1244-8.
24. Nwokolo C U, Smith J T, Gavey C, Sawyerr A, Pounder R E. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4: 29-45.
25. Sandvik A K, Brenna E, Waldum H L. Review article: The pharmacological inhibition of gastric acid secretion - Tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013-18.
26. Hirota K, Kushikata T. Preanesthetic H2 antagonists for acid aspiration pneumonia prophylaxis. Is there evidence of tolerance? Br J Anaesth 2003; 90: 576-9.
27. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
28. Wesdorp E, Bartelsman J, Pape K, Dekker W, Tytgat G N. Oral cimetidine in reflux esophagitis: A double blind controlled trial. Gastroenterology 1978; 74: 821-4.
29. Koelz H R, Birchler R, Bretholz A et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198-205.
30. Morris A I. The success of histamine-2 receptor antagonists. Scand J Gastroenterol Suppl 1992; 194: 71-5.